Indications
Orphacol is indicated for the treatment of inborn errors in primary bile acid synthesis due to3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency ininfants, children and adolescents aged 1 month to 18 years and adults.
Composition
- Active substance
- cholic acid
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Orphacol
- Active substance
- cholic acid
- ATC code
- A05AA03
- Therapeutic area
- Digestive System Diseases, Metabolism, Inborn Errors
- Marketing authorisation holder
- Theravia
- Status